Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
OTHER OTC:SPRB
SPRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.06 - $0.61
Previous CloseN/A
Volume285.87K
Average Volume (3M)239.99K
Market Cap
$3.04M
Enterprise Value$379.00M
Total Cash (Recent Filing)$25.61M
Total Debt (Recent Filing)$2.00M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 06, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding42,231,285
10 Day Avg. Volume302,179
30 Day Avg. Volume239,994
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)-12.35
Price to Sales (P/S)0.00
P/FCF Ratio-29.99
Enterprise Value/Market Cap124.65
Enterprise Value/Revenue15.47
Enterprise Value/Gross Profit130.29
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$0.75Price Target Upside971.43% Upside
Rating ConsensusHold
Number of Analyst Covering4
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences’ Compliance Plan Accepted by Nasdaq
PremiumCompany Announcements
Spruce Biosciences Enters Purchase Agreement with Board Chair
PremiumCompany Announcements
Spruce Biosciences Reports Q1 2025 Results and Updates
PremiumCompany Announcements
Spruce Biosciences Acquires TA-ERT for Rare Disease FocusBulls Say, Bears Say
Bulls Say
Regulatory ApprovalThe FDA confirmed that HS-NRE is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for Accelerated Approval.
Strategic DevelopmentsSpruce Biosciences acquired tralesinidase alfa, an enzyme replacement therapy, originally developed by BioMarin, which is in late-stage development and has a seemingly de-risked path to approval.
Bears Say
Financial PerformanceSPRB reported a net loss of $14.0M for the quarter.
Liquidity ConstraintsSPRB's cash balance is now less than $30M and the company is facing significant liquidity pressure.
Ownership Overview
9.22% Insiders
2.52% Mutual Funds
17.56% Other Institutional Investors
70.70% Public Companies and Individual Investors
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.06 and its highest was $0.61 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $3.04M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Aug 06, 2025 which is in 37 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on May 06, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.257 by -$0.063.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -0.26.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 42,231,285 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.257. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at 0.
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Stock 12 Month Forecast
Average Price Target
$0.75
▲(971.43%Upside)
Technical Analysis
Kazia Therapeutics
―
Windtree Therapeutics
―
Xenetic Biosciences
―
180 Life Sciences
―
Alzamend Neuro
―